Short Interest in Trinity Biotech plc (NASDAQ:TRIB) Decreases By 50.3%

Trinity Biotech plc (NASDAQ:TRIB) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 29,100 shares, a decline of 50.3% from the December 15th total of 58,500 shares. Based on an average trading volume of 207,300 shares, the short-interest ratio is presently 0.1 days. Approximately 0.3% of the shares of the stock are sold short.

Trinity Biotech Price Performance

TRIB stock traded up $0.03 during trading on Thursday, hitting $0.82. 90,690 shares of the company’s stock traded hands, compared to its average volume of 243,566. Trinity Biotech has a 52 week low of $0.75 and a 52 week high of $3.55. The business has a fifty day simple moving average of $1.04 and a 200 day simple moving average of $1.72.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC boosted its position in shares of Trinity Biotech plc (NASDAQ:TRIB) by 7.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 359,810 shares of the company’s stock after purchasing an additional 26,100 shares during the period. Hunter Associates Investment Management LLC owned about 4.72% of Trinity Biotech worth $390,000 as of its most recent SEC filing. Institutional investors own 78.97% of the company’s stock.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.